Biotechnology Sector

In an era marked by escalating global food insecurity and climate volatility, minimizing food loss and waste has emerged as a paramount priority across agricultural and supply chain sectors. Recent insights underscore that approximately 30% of global food production is lost primarily due to inefficiencies in postharvest handling and insufficient storage technologies. This staggering level

In recent years, there has been growing interest in the relationship between dietary compounds and liver health. A recent study conducted by Ding et al. has shed light on the toxicological potential of naringin, a flavonoid commonly found in citrus fruits. This research aims to uncover the mechanisms behind liver injury that may be induced

The opioid crisis has reached alarming levels, with rapid increases in the number of overdose deaths across various demographics. An emerging body of research has begun to scrutinize the implications of tapering opioid prescriptions, particularly among individuals who are on high-dose and long-term opioid therapy. A recent study by Song et al. delves into this

A revolutionary study sheds light on the aging process of the ovaries, placing extracellular vesicles derived from mesenchymal stem cells in the spotlight as game-changers in women’s reproductive health. Conducted by a team led by researchers Zhang, Chang, and Chang, this groundbreaking research promises to redefine our understanding of ovarian aging, particularly its inflammation-related aspects.

Despite the advancements in healthcare technology, the nursing profession continues to grapple with significant levels of burnout and disengagement among practitioners. In a recent study published in BMC Nursing, researchers, including Chung, Jung, and Park, delve deep into the dual impacts of digital literacy and nursing informatics competency on this pressing issue. By analyzing the

The liver is a vital organ that performs numerous functions, including the detoxification of blood, the production of essential proteins, and the regulation of metabolism. In pediatric populations, particularly among those diagnosed with biliary atresia, liver health becomes an even more critical concern. Biliary atresia is a severe condition where the bile ducts are either

Groundbreaking Study Uses Single-Nucleus RNA Sequencing to Unravel Brown/Beige Adipose Tissue Dynamics Post-Bariatric Surgery In a remarkable advancement within the field of metabolic research, a team of scientists led by Wang and colleagues has employed cutting-edge single-nucleus RNA sequencing technology to dissect the complex microenvironmental dynamics of brown and beige adipose tissues following bariatric surgery.

In Singapore, the healthcare landscape is evolving to address the unique challenges faced by its aging population. As the incidence of geriatric syndromes continues to rise, driven by an increasing elderly demographic, healthcare professionals are compelled to find innovative solutions to manage these complex health issues effectively. A pivotal study led by a team of

In recent years, mental health has emerged as a focal point of health care discussions, primarily due to the growing recognition of its impact on overall well-being. A key component of effective mental health care lies in the emotional resilience of health care providers. The concept of empathy in patient care—while invaluable—often puts mental health

In the quest to understand the dynamics of agricultural expansion and its implications on sustainability, a groundbreaking study has shed light on the historical and potential future distribution of paddy rice fields across Asian highlands. This investigation, led by Song, Wang, Nunes, and colleagues, provides unprecedented insight into how these vital food-producing landscapes have evolved

In the evolving landscape of urban transportation, the need for effective solutions in hazardous materials transportation, particularly within the context of electric vehicles, is becoming increasingly critical. The recent research conducted by Zhang, Q., Zhang, Z., and Ma, C. delves deep into this pivotal area, advancing the discussion around multi-objective route optimization in uncertain environments.

In a groundbreaking study, researchers have unveiled significant connections between visceral fat and arterial stiffness progression in individuals suffering from Type 2 diabetes. The study, led by an esteemed team including Li, Yin, and Zhao, investigates the implications of the Metabolic Score for Visceral Fat (METS-VF) in a retrospective cohort of patients from China. This

In a significant advancement in the treatment of pancreatic cancer, researchers have explored the efficacy of neoadjuvant stereotactic body radiation therapy (SBRT) paired with intraoperative electron radiotherapy during surgical resection. This innovative approach aims to enhance treatment outcomes for one of the most challenging malignancies known for its lethality. The study, spearheaded by Cornejo and

In recent years, the field of epilepsy treatment has witnessed significant advancements, with many new medications being developed to provide relief for patients suffering from this debilitating condition. A recent study led by Yu et al. has focused on the innovative drug, cenobamate, which has emerged as a promising adjunctive therapy for individuals experiencing focal

Obesity has emerged as one of the most pressing public health challenges of the 21st century. With its impacts spreading across various dimensions of health, understanding the biological mechanisms behind obesity has become a prime focus of scientific inquiry. Recent research by Liu, Wang, and Liu sheds light on the differential roles of coding and

Recent groundbreaking research has illuminated a vital link between sustainable soil management practices and enhanced crop defenses, a discovery that could signal a transformative shift in agricultural paradigms worldwide. At the heart of this revelation is the intricate relationship between the soil microbiome and plant immunity. By carefully managing soil health, farmers can inadvertently bolster

In the evolving landscape of neonatal care, accurate and timely assessment of bilirubin toxicity remains a critical issue, especially for newborns vulnerable to hyperbilirubinemia. A groundbreaking study published in Pediatric Research on December 22, 2025, has shed new light on the bilirubin-albumin molar ratio (BAMR) as a potentially reliable screening tool for elevated unbound bilirubin

Time-Restricted Feeding and Its Metabolic Impact on Rodent Obesity Models: A Detailed Analysis The burgeoning interest in time-restricted feeding (TRF) as a potential intervention for obesity and metabolic dysregulation has spurred a variety of studies investigating its efficacy. A recent comprehensive review published in the International Journal of Obesity by Argaistieng et al. (2025) presents

In a groundbreaking new study published in the International Journal of Obesity, researchers Çelik and Ulug have provided compelling insights into the complex relationship between ultra-processed foods (UPF) and short-term appetite regulation. For years, the role of processed and ultra-processed foods in influencing eating behavior and weight management has been a subject of heated debate

In a groundbreaking study published in the Journal of Ovarian Research, researchers Ma and Sun reveal significant insights into the mechanisms underlying premature ovarian insufficiency (POI), a condition affecting a notable percentage of women globally. This condition, characterized by a significant decline in ovarian function before the age of 40, poses important challenges not only

Six people, including a former employee of investment bank Citigroup’s San Francisco office, have been charged in an alleged $41 million insider trading and stock manipulation scheme that involves two biotech companies.

Amid news of the splashy $4.8 billion Amicus buy, BioMarin has slipped in the discontinuation of a genetic lung disease candidate it had once hoped would become a best-in-class treatment.

Two years after Gilead secured the first option on Assembly Biosciences’ entire pipeline, the pharma has decided to pick the first fruits from the pact.

Boehringer Ingelheim has opened another front in its attack on chronic kidney disease, offering Rectify Pharmaceuticals up to $448 million to partner on a preclinical program.

Dive into the world of biotech cinema this holiday season! Our list of biotech movies offers the perfect blend of science and entertainment. The post The best biotech movies to watch this winter appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Big Pharma-backed Aktis Oncology has announced plans to go public in the latest encouraging sign for those betting on a resurgence in biotech IPOs next year.

Having kicked off the year with a $200 million series A, Windward Bio is ending 2025 splashing out on another clinical-stage drug.

Ipsen may be a recent entrant into the antibody-drug conjugate space, but the French biopharma is continuing to make up for lost time.

A phase 3 study of AstraZeneca’s ceralasertib has missed its primary endpoint, dealing another blow to efforts to use a synthetic lethal mechanism to overcome resistance to immuno-oncology drugs.

AstraZeneca has fronted $100 million to head deeper into the KRAS space, securing the rights to a clinical-stage, multitarget asset from China’s Jacobio Pharma.

Ipsen’s oral small molecule failed to reduce the progression of a genetic disease that gradually turns tendons and ligaments into bone, prompting the pharma to stop the study early.

A strict new vaccine approval process in the U.S. could dramatically slow things down for biopharma and the public, experts warn. The post U.S. vaccine approvals to undergo overhaul: what do the changes mean?  appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Venture capital firm Aditum Bio is going all-out for a new collaboration with Fosun Pharma, launching a subsidiary with the sole purpose of developing novel therapies in tandem with the Shanghai-based drugmaker.

Merck & Co. is turning down its option to license Evaxion’s gonorrhea vaccine candidate, closing the door on the Danish biotech’s chance to collect up to $592 million in biobucks.

Today's guest is J&J's Ester in t’Groen and we will discuss what's next for J&J in hematology in 2026—including some exciting readouts. The post Johnson & Johnson’s hematology portfolio: breakthroughs to watch appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Altimmune has shared an update on the metabolic dysfunction-associated steatohepatitis (MASH) study that sank its stock in June. The 48-week readout linked the top dose of the GLP-1/glucagon dual receptor agonist to continued weight loss and improvements on noninvasive measures of liver fibrosis.

Boehringer Ingelheim has turned down its chance to license Nxera Pharma’s phase 2-ready schizophrenia drug candidate, depriving the Japanese drugmaker of a 60 million euro ($70 million) option payment.

Longtime Pfizer R&D chief Kathy Fernando, Ph.D., has left the Big Pharma behind to take on the role of chief business officer at San Diego biotech Replicate Bioscience. There, she’ll work to advance Replicate’s early-stage pipeline of assets built on self-replicating RNA technology.

After a long and strange year, Belgian biotech Galapagos is closing out 2025 with some mixed results for its last remaining immunology asset. The company’s tyrosine kinase 2 inhibitor GLPG3667 met the primary endpoint in a dermatomyositis study, but failed to do the same when tested in systemic lupus erythematosus.

After taking a stab at becoming a neuroscience biotech, buzzy Bay Area AI outfit Verge Genomics is dropping its only clinical asset and returning to its drug discovery roots.

Daiichi Sankyo and Merck & Co.’s phase 3 program for their investigational antibody-drug conjugate has been hit with a hold after an unexpected number of deaths were reported in the global trial.

Founded by a team of neuropsychiatric-focused Teva alums and the force behind Cobenfy maker Karuna, Syremis Therapeutics is off to the races with a $165 million series A to support the development of a dual M1/M4 agonist in schizophrenia.

Athira Pharma has joined an attempt to rescue an asset abandoned by Pfizer. The biotech has secured near-global rights to a phase 3 breast cancer prospect in a deal with Sermonix Pharmaceuticals.

The Coalition for Epidemic Preparedness Innovations—already engaged in a strategic partnership with Moderna—has agreed to plug up to $54.3 million into a pivotal phase 3 trial for mRNA-1018, Moderna’s mRNA-based H5 pandemic influenza vaccine candidate.

Eli Lilly has shown patients maintained most of their weight loss after switching from injectable GLP-1s to its oral drug candidate, teeing the drugmaker up to target people taking Novo Nordisk’s Wegovy.

GSK is embarking on a journey with CAMP4 Therapeutics, paying $17.5 million upfront to collaborate on regulatory RNA-targeting therapeutics in neurodegenerative and kidney disease indications.

Takeda’s closely watched and highly valued dermatology pill zasocitinib has won out in two key phase 3 trials as the Japanese pharma looks to file the drug in the U.S. next year.

Discover eight of the biggest immunology and inflammation (I&I) deals in 2025, from early-stage collaborations to late-stage licensing deals. The post Eight of the biggest immunology and inflammation (I&I) deals in 2025 appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Take a look back into biotech in 2025 as the year is closing - from GLP-1s to radiopharmaceuticals and neuroplastogens. The post Biotech in 2025: A retrospective  appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

BIO-Europe Startup Spotlight returns to Lisbon in March 2026, showcasing Europe’s top early-stage biotech pitches to industry leaders. The post Lisbon is calling: the BIO-Europe Startup Spotlight returns in March 2026 appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Some companies have had wins in 2025, while others have major milestones coming up. Here are 15 biotechs to watch as we head into 2026. The post Keep an eye on these 15 biotech companies in 2026  appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Explore our curated list of biotechnology-themed gifts, ranging from captivating board games to engaging DIY biology kits. The post Fifteen gift ideas for a biotech enthusiast this holiday season appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

In this episode we sit down with Martin Beck, Senior Vice President and Head of the Inflammation Business Unit at Boehringer Ingelheim. The post Tackling pulmonary fibrosis: Boehringer Ingelheim’s new drug + AI approach appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Find out whether a promising cure for COPD is within reach, after recent advancements in treatments and research around the disease. The post Promising cure for COPD: Is a breakthrough treatment within reach? appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Discover what the next wave of AI-assisted drug discovery looks like and how it can help biotech - the AI and physics combo. The post When AI isn’t enough: How physics is shaping the next wave of drug discovery  appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Ghent is boosting its biopharma hub with cutting-edge infrastructure, world-class research, and a thriving life sciences community. The post How world-class infrastructure will reinforce Ghent’s position as Europe’s biopharma hub appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Navigating the Complex World of Global Drug Patents: Strategies and Challenges Ahead As a pharmaceutical professional, you know how crucial it is to protect your innovative drug patents in the global market. With the rise of international trade and the... Source

The Complex World of Biologic Drugs: Navigating Patent Applications As a biotech professional, you're likely no stranger to the intricacies of developing life-saving treatments. But when it comes to biologic drugs, the process can be particularly chall... Source

Unlocking the Power of Combination Therapies: Strategies for Successful Patenting As a pharmaceutical professional, you know that combination therapies have revolutionized the treatment of complex diseases. By pairing two or more active ingredients, yo... Source

The Secret to Setting the Right Price for Your Generic Medications As a generic drug manufacturer, you're constantly looking for ways to stay ahead of the competition and bring affordable medications to market. But have you ever wondered how to set the... Source

Unlocking Efficiency in the Generic Drug Supply Chain As the pharmaceutical industry continues to evolve, the generic drug supply chain has become a critical component of ensuring timely and affordable access to life-saving medications. However, naviga... Source

Breaking News: FDA Updates - What Do the Latest Changes Mean for Generic Drug Approval? As a healthcare professional or a business leader in the pharmaceutical industry, you're likely aware of the complex landscape surrounding generic drug approval. Re... Source

Breaking Down Barriers: Navigating Regulatory Challenges in Latin America's Generic Drug Market As the demand for affordable generic medications continues to grow, Latin America has emerged as a critical region for pharmaceutical companies looking to e... Source

The Future of Affordable Healthcare: Can Biosimilars Deliver? As healthcare professionals, we're constantly on the lookout for innovative solutions to improve patient outcomes while reducing costs. One promising approach is the use of biosimilars – bio... Source

Ensuring the Highest Quality in Generic Medications: A Crucial Step in Healthcare As the global demand for affordable healthcare continues to rise, generic medications have become a vital lifeline for millions of people worldwide. However, with the inc... Source

The Unseen Heroes of Generic Medicines: The Crucial Role of Quality Assurance As we navigate the complex world of pharmaceuticals, it's easy to overlook the unsung heroes behind the scenes. But today, I want to shine a spotlight on the Quality Assuranc... Source

Can Lurbinectedin Treat Ovarian Cancer? A Comprehensive Review Ovarian cancer is a devastating disease that affects thousands... https://www.Drugchatter.com/chat/25460/can-lurbinectedin-treat-ovarian-cancer/ Source

Unlocking the Potential of Biosimilars: Navigating Regulatory Considerations for Clinical Efficacy Trials As the pharmaceutical industry continues to evolve, biosimilars have emerged as a game-changer in the quest for affordable and accessible treatmen... Source

Unlock the Secrets of Drug Patent Searching: A Beginner's Guide As a professional in the pharmaceutical industry, staying ahead of the curve is crucial. One of the most critical aspects of this is understanding the world of drug patents. But have you e... Source

Unlocking the Path to Generic Medication Approval: A Step-by-Step Guide As a healthcare professional or a business leader in the pharmaceutical industry, you're likely aware of the complex landscape surrounding generic medication approval. With the eve... Source

The Future of Biosimilars: Switching Strategies for Success As the biosimilar market continues to grow, one question on everyone's mind is: how can we make the most of this opportunity? One strategy that's gaining traction is biosimilar-to-biosimilar s... Source

The Hidden Factors Behind FDA-Approved Drugs' Patent Challenges As a healthcare professional or a pharmaceutical industry expert, you're likely no stranger to the complex world of drug patents. But have you ever wondered what sets some FDA-approved dru... Source

Breaking Down Barriers: The Power of Partnerships in Generic Drug Development As the pharmaceutical industry continues to evolve, one thing is clear: collaboration is key. In the world of generic drug development, partnerships are playing an increasing... Source

Does Fish Oil Interact with Vascepa? A Comprehensive Guide As the world becomes increasingly aware of the importance of... https://www.Drugchatter.com/chat/45752/does-fish-oil-interact-with-vascepa/ Source

The Art of Timing: Mastering Generic Drug Development Timelines As a seasoned professional in the pharmaceutical industry, you know that navigating the complex landscape of generic drug development can be a daunting task. One of the most critical facto... Source

The Impact of Lipitor on White Wine: A Comprehensive Guide As a popular cholesterol-lowering medication, Lipitor (atorvastatin)... https://www.Drugchatter.com/chat/37341/how-does-lipitor-affect-white-wine/ Source

The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.

With significant growth in activities globally, our /local page has strained to keep up and simply is not a great...